The Canadian nuclear reactor that satisfies more than half of demand of molybdenum-99 for medical nuclear imaging services in North America will not return to service until the first quarter of 2010.
The Canadian nuclear reactor that satisfies more than half of demand of molybdenum-99 for medical nuclear imaging services in North America will not return to service until the first quarter of 2010.
Atomic Energy Canada Limited announced Wednesday that it was rolling back the estimated startup date for the National Research Universal reactor at Chalk River, ON. The reactor was shut down May 14 after a heavy-water leak penetrating its vessel wall was discovered. AECL initially estimated repairs would be completed in late 2009.
The shutdown triggered a widespread shortage of Mo-99, the precursor isotope necessary for the production of technetium-99m, a radioisotope used in a majority of nuclear medicine procedures. Most nuclear medicine departments in the U.S. and Canada were affected. The situation worsened in June when the High Flux Reactor at Petten, the Netherlands, another important source of Mo-99 production, was shut down for planned routine maintenance.
Dr. Jean-Luc Urbain, chairman of nuclear medicine at the University of Western Ontario in London, told Diagnostic Imaging during an Aug. 4 interview that his department was receiving only 40% of its usual Mo-99 consignment. As with many facilities in Canada and the U.S., his clinic had delayed noncritical imaging procedures and shifted to thallium-201 for nuclear cardiology and FDG PET for cancer diagnosis and staging.
AECL rolled back its reactor startup date to Q1 2010 after a nondestructive survey of the containment vessel identified nine sites of corrosive wall-thinning requiring repair.
Safety-related problems at the NRU reactor have been the cause of two extended medical isotope shortages since 2007. The current incident triggered calls in the U.S. for Congress to approve funding to reestablish a domestic source of Mo-99. The last domestic provider ceased operations in 1989.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.